# Entrada Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/entrada-therapeutics

- Industry: Biotechnology
- Headquarters: Boston, US
- Website: www.entradatx.com
- Total disclosed funding: $153M
- Latest round: Series B (Mar 29, 2021)
- Investors on record: 14

## About

Based in Boston, US and founded in 2016 by Dehua Pei and Leo Qian, Entrada Therapeutics, Inc. is a biotechnology company that develops treatments for devastating diseases using intracellular biologics. Entrada Therapeutics has raised a total of USD 175.60 million in funding over 3 rounds. In March 2021, Entrada Therapeutics, Inc. raised USD 116 million in series B funding led by new investor Wellington Management Company. In October 2021, the company raised USD 181.5 million in its IPO and got listed on NASDAQ under the ticker symbol TRDA.

Entrada Therapeutics, Inc. develops and sells Endosomal Escape Vehicle (EEVTM) technology, which allows for the efficient intracellular delivery of proteins, peptides, and nucleic acids, allowing for the development of programs for intracellular target classes and the treatment of a variety of neuromuscular diseases.

Entrada Therapeutics, Inc. intends to move its platform and pipeline into clinical trials.

## Funding rounds

- Series B, Mar 29, 2021, $116M — Greenspring Associates, 5AM Ventures, Qatar Investment Authority, MPM BioImpact, Goldman Sachs Asset Management, Roche Venture Fund, Redmile Group, Point72 Asset Management, Agent Capital, Wellington Management Company, Moore Strategic Ventures, MRL Ventures Fund, CureDuchenne Ventures, TCG Crossover Management
- Series A, Dec 18, 2018, $36M — 5AM Ventures, MPM BioImpact, Roche Venture Fund, Agent Capital, MRL Ventures Fund

## Investors

- 5AM Ventures (https://capitalatlas.ai/funds/5am-ventures) — Series A, Series B
- MPM BioImpact (https://capitalatlas.ai/funds/mpm-bioimpact) — Series A, Series B
- Roche Venture Fund (https://capitalatlas.ai/funds/roche-venture-fund) — Series A, Series B
- Agent Capital (https://capitalatlas.ai/funds/agent-capital) — Series A, Series B
- MRL Ventures Fund (https://capitalatlas.ai/funds/mrl-ventures-fund) — Series A, Series B
- Greenspring Associates (https://capitalatlas.ai/funds/greenspring-associates) — Series B
- Qatar Investment Authority (https://capitalatlas.ai/funds/qatar-investment-authority) — Series B
- Goldman Sachs Asset Management (https://capitalatlas.ai/funds/goldman-sachs-asset-management) — Series B
- Redmile Group (https://capitalatlas.ai/funds/redmile-group) — Series B
- Point72 Asset Management — Series B
- Wellington Management Company — Series B
- Moore Strategic Ventures (https://capitalatlas.ai/funds/moore-strategic-ventures) — Series B
- CureDuchenne Ventures (https://capitalatlas.ai/funds/cureduchenne-ventures) — Series B
- TCG Crossover Management (https://capitalatlas.ai/funds/tcg-crossover-management) — Series B